NSE: ALKEM · 7 October 2026
- Alkem Laboratories Ltd. shares are trading higher by 1.11% at ₹5,350.50 on the NSE, moving within a day's range of ₹5,293.50 and ₹5,403.00 after opening at ₹5,365.50.
- Alkem Laboratories informed the exchange that it has issued a corporate guarantee amounting to Euro 54.45 million to HSBC UK Bank plc. This guarantee backs a term loan of Euro 49.5 million availed by M/s. Occlutech Holding AG, a step-down subsidiary of the company in Switzerland. The company noted that this represents a contingent liability that would become payable only if the subsidiary defaults.
- Trading volume was 1.29 times the 20-day average daily volume.
Why is Alkem Laboratories share price rising on 7 October 2026?
Alkem Laboratories Ltd. shares are trading higher by 1.11% at ₹5,350.50 on the NSE, moving within a day's range of ₹5,293.50 and ₹5,403.00 after opening at ₹5,365.50.
The broader market sentiment was subdued as the Nifty slipped 0.76% and the Nifty Pharma sector benchmark declined by 0.43%, reflecting relative outperformance by the stock against its sectoral peers. The equity has also posted a positive return of 1.91% over the trailing 5 trading days and 3.27% over the past 20 trading days.
While no single immediate exchange filing was published today to trigger the session's gains, the company recently announced the launch of NeuCeno (cenobamate) for the treatment of partial-onset seizures on September 16, 2026, and a corporate guarantee of Euro 54.45 million issued for its Swiss subsidiary Occlutech Holding AG on September 21, 2026. These developments provide ongoing strategic context rather than a direct catalyst for today's price action.
1.97 lakh shares traded by 7 October 2026 · 03:15 PM IST. This compares with a 20-day average daily volume of 1.52 lakh shares (1.29 times). The five-day average daily volume was 1.70 lakh shares. Separately, the NSE report for 6 October 2026 showed 33,361 shares delivered, representing 52.40% of that day’s traded volume. The same report recorded 10,111 trades.
The move appears driven by stock-specific accumulation and above-average cash volume rather than a confirmed same-day news catalyst, outperforming a weak broader pharmaceutical sector.
Latest Company Developments
Alkem Laboratories informed the exchange that it has issued a corporate guarantee amounting to Euro 54.45 million to HSBC UK Bank plc. This guarantee backs a term loan of Euro 49.5 million availed by M/s. Occlutech Holding AG, a step-down subsidiary of the company in Switzerland. The company noted that this represents a contingent liability that would become payable only if the subsidiary defaults.
It establishes a notable financial commitment and contingent liability supporting the international expansion and capital requirements of its step-down subsidiary.
The company announced the commercial launch of NeuCeno (cenobamate) as an anti-seizure medication for adult patients suffering from partial-onset seizures. Being introduced for the first time in India, the once-daily oral therapy aims to address the significant healthcare burden of epilepsy by offering a dual mechanism of action.
Expanding into specialized chronic therapies like neurology strengthens Alkem's product portfolio in high-unmet-need segments beyond its core acute offerings.
Alkem Laboratories disclosed that Mr. Nitin Agrawal resigned from his position as Chief Financial Officer and Key Managerial Personnel on July 30, 2026, to pursue new professional opportunities, with his cessation taking effect from September 30, 2026. The required regulatory disclosures regarding the change in senior management were duly submitted to the stock exchanges.
Leadership transitions in key financial roles require monitoring for continuity in corporate governance, financial reporting, and strategic execution.
a press release dated September 16, 2026, titled "Press Release Alkem Laboratories Limited launches NeuCeno (cenobamate) for the treatment of partial-onset seizures in adult patients.".
Change in Key Managerial Personnel Resignation of Chief Financial Officer.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 16.71% on 30 June 2026. This compares with 15.57% on 31 March 2026, a change of +1.14 percentage points.
The filing reported 29 MF/UTI holders.
Research & Brokerage Views
Maintained a neutral stance with a target price of ₹5,770 following Q1 earnings results that featured a profit beat.
Historical Bulk / Block Deals
What to Watch Next
- Execution progress and adoption rates following the launch of NeuCeno (cenobamate) in domestic neurology markets
- Updates on the transition and appointment process for the Chief Financial Officer following the cessation of Mr. Nitin Agrawal
- Performance trends in key chronic and specialty therapeutic segments in upcoming financial results
- Sustained cash-market volume and delivery percentage relative to the 20-day average volume of 1.29x
Other Dated Coverage
- Why Alkem Laboratories Shares Fell 2.24% Today: Sector Trends in Focus | 1 October 2026 — 1 October 2026
- Why Alkem Laboratories Shares Fell 1.65% Today: Sector Trends | 30 September 2026 — 30 September 2026
More Alkem Laboratories news and dated analysis →
Frequently Asked Questions
What is the latest Alkem Laboratories company news?
Alkem Laboratories informed the exchange that it has issued a corporate guarantee amounting to Euro 54.45 million to HSBC UK Bank plc. This guarantee backs a term loan of Euro 49.5 million availed by M/s. Occlutech Holding AG, a step-down subsidiary of the company in Switzerland. The company noted that this represents a contingent liability that would become payable only if the subsidiary defaults.
How strong was Alkem Laboratories’s trading volume?
1.97 lakh shares traded, 1.29 times the 20-day average daily volume. The price and volume data are dated 7 October 2026 · 03:15 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 June 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.